Portfolio Sync Solutions
Streamline your investment strategy with our portfolio synchronization tools. Seamlessly manage and track your holdings across platforms for enhanced
GET STARTEDDay One Biopharmaceuticals, Inc. Analyst EPS Estimates
| Quarter | Number of Estimates | Low Estimate | High Estimate | Average Estimate |
|---|---|---|---|---|
| Q1 2024 | 2 | -$0.80 | -$0.69 | -$0.75 |
| Q2 2024 | 2 | -$0.34 | -$0.29 | -$0.32 |
| Q3 2024 | 6 | -$1.07 | -$0.32 | -$0.46 |
| Q1 2025 | 3 | -$0.35 | -$0.29 | -$0.32 |
| Q2 2025 | 2 | -$0.27 | -$0.24 | -$0.26 |
| Q3 2025 | 2 | -$0.22 | -$0.19 | -$0.21 |
| Q4 2025 | 2 | -$0.15 | -$0.13 | -$0.15 |
| Q1 2026 | 1 | -$0.36 | -$0.31 | -$0.33 |
| Q2 2026 | 1 | -$0.37 | -$0.32 | -$0.35 |
| Q3 2026 | 1 | -$0.40 | -$0.35 | -$0.38 |
| Q4 2026 | 1 | -$0.42 | -$0.36 | -$0.39 |
Day One Biopharmaceuticals, Inc. Earnings Date And Information
Day One Biopharmaceuticals, Inc. last posted its earnings results on Wednesday, October 30th, 2024. The company reported $0.38 earnings per share for the quarter, topping analysts' consensus estimates of $-0.41 by $0.79. The company had revenue of 93.76 M for the quarter and had revenue of 0 for the year. Day One Biopharmaceuticals, Inc. has generated $-2 earnings per share over the last year ($-2.37 diluted earnings per share) and currently has a price-to-earnings ratio of -14.52. Day One Biopharmaceuticals, Inc. has not formally confirmed its next earnings publication date, but the company's estimated earnings date is Monday, February 24th, 2025 based on prior year's report dates.
Day One Biopharmaceuticals, Inc. Earnings History by Quarter
| Date | Quarter | Consensus Estimate | Reported EPS | Beat/Miss | Revenue Estimate | Actual Revenue |
|---|---|---|---|---|---|---|
| 10/30/2024 | Q3 2024 | -$0.41 | $0.38 | 0.79 | $28.48 M | $93.76 M |
| 08/02/2024 | Q2 2024 | -$0.05 | $1.03 M | $8.19 M | ||
| 05/06/2024 | Q1 2024 | -$0.67 | -$0.72 | -0.05 | $0 | |
| 02/26/2024 | Q4 2023 | -$0.57 | -$0.62 | -0.05 | $560,000 | |
| 11/06/2023 | Q3 2023 | -$0.60 | -$0.54 | 0.06 | $0 | |
| 08/07/2023 | Q2 2023 | -$0.60 | -$0.61 | -0.01 | $0 | |
| 05/01/2023 | Q1 2023 | -$0.60 | -$0.49 | 0.11 | $0 | |
| 03/06/2023 | Q4 2022 | -$0.57 | -$0.47 | 0.1 | $0 | |
| 11/07/2022 | Q3 2022 | -$0.53 | -$0.48 | 0.05 | $0 | |
| 08/04/2022 | Q2 2022 | -$0.49 | -$0.60 | -0.11 | $0 | |
| 05/12/2022 | Q1 2022 | -$0.39 | -$0.48 | -0.09 | $0 | |
| 03/07/2022 | Q4 2021 | -$0.36 | -$0.38 | -0.02 | $0 | |
| 11/08/2021 | Q3 2021 | -$0.28 | -$0.33 | -0.05 | $0 | |
| 08/10/2021 | Q2 2021 | -$0.31 | -$5.04 | -4.73 | $0 | |
| 03/30/2021 | Q1 2021 | -$0.25 | $0 | |||
| 12/30/2020 | Q4 2020 | -$0.82 | $0 | |||
| 09/29/2020 | Q3 2020 | -$0.07 | $0 | |||
| 06/29/2020 | Q2 2020 | -$0.04 | $0 | |||
| 03/30/2020 | Q1 2020 | -$0.04 | $0 |
Day One Biopharmaceuticals, Inc. Earnings: FAQ's
When is Day One Biopharmaceuticals, Inc.'s earnings date?
Day One Biopharmaceuticals, Inc. has not confirmed its next earnings publication date, but the company's estimated earnings date is Monday, February 24th, 2025 based off last year's report dates.
Did Day One Biopharmaceuticals, Inc. beat their earnings estimates last
quarter?
In the previous quarter, Day One Biopharmaceuticals, Inc. (:DAWN) reported $0.38 earnings per share (EPS) to beat the analysts' consensus estimate of $-0.41 by $0.79.
How can I listen to Day One Biopharmaceuticals, Inc.'s earnings conference
call?
The conference call for Day One Biopharmaceuticals, Inc.'s latest earnings report can be listened to online.
How can I read Day One Biopharmaceuticals, Inc.'s conference call transcript?
The conference call transcript for Day One Biopharmaceuticals, Inc.'s latest earnings report can be read online.
How much profit does Day One Biopharmaceuticals, Inc. generate each year?
Day One Biopharmaceuticals, Inc. (:DAWN) has a recorded net income of $0. Day One Biopharmaceuticals, Inc. has generated $-2.37 earnings per share over the last four quarters.
What is Day One Biopharmaceuticals, Inc.'s price-to-earnings ratio?
Day One Biopharmaceuticals, Inc. (:DAWN) has a price-to-earnings ratio of -14.52 and price/earnings-to-growth ratio is -0.3.